The UK is racing to sequence every newborn – so why do we still skip the genome before pregnancy?

Article produced in association with Jeen Health

Britain has committed serious money and political will to genomics at birth and during pregnancy. The one window it keeps overlooking is the cheapest and most actionable of all – the months before conception.

A screening timeline with a gap at the start

The UK has rarely been more ambitious about genomics.

Under the 10-Year Health Plan’s “shift to prevention,” NHS England has set out an intention to offer whole-genome sequencing to every newborn, with a national rollout planned to begin this year.

It builds on Genomics England’s Generation Study, a research programme sequencing the genomes of 100,000 babies to look for more than 200 rare but treatable conditions.

Map the current screening pathway, though, and a pattern emerges.

At birth, the NHS heel-prick test screens for a small set of rare conditions – currently ten. During pregnancy, NIPT and ultrasound assess the developing fetus.

After birth, genome sequencing is now moving from research towards routine. Each of these stages has had investment, attention and infrastructure poured into it.

The one stage that has not is the earliest of all: before conception. It is the cheapest point at which to act, the one where the widest range of options is still open, and – not coincidentally – the least systematised.

Why before conception is the highest-leverage point

The clinical logic is straightforward. Most serious inherited conditions are recessive: a child is only affected if they inherit a faulty copy of the same gene from both parents.

Carriers typically have no symptoms and no family history, so the overwhelming majority never discover they carry anything until an affected child arrives.

When both partners carry the same recessive condition, every pregnancy carries a one-in-four chance of an affected child. Learning that before pregnancy keeps the full menu of options on the table: conceiving naturally with informed monitoring, IVF with preimplantation genetic testing, the use of donor gametes, or simply preparing with the right specialists in place.

Discover the same information at twelve weeks and the choices are fewer, harder and far more time-pressured.

The test that surfaces this is not exotic. Jeen Health, for one, offers counsellor-led carrier testing taken from home before pregnancy, flagging the recessive conditions where both partners happen to carry the same variant – the handful that are actually relevant to a given couple.

In health-economic terms it is prevention at its most efficient: a single test, taken before the clock starts, that can reshape an entire reproductive pathway and pre-empt a lifetime of downstream cost.

So why isn’t it routine?

The NHS does offer carrier screening, but only in targeted circumstances – a known family history, or membership of a population at higher risk for a specific condition.

Comprehensive, multi-condition screening for the general population is not routinely available.

Whether a test is offered to everyone is a policy decision taken by the UK National Screening Committee, which weighs evidence, cost, equity and – crucially – the system’s capacity to act responsibly on the results.

That produces a striking asymmetry.

The health service is preparing to sequence whole genomes at birth, yet stops short of offering broad carrier screening to the adults actively planning a family – the very group best placed to use the information while it still changes their options.

Some of that caution is genuine and instructive: a population screening programme is only ever as good as the support wrapped around it.

The counselling bottleneck

Carrier screening is not a simple pass or fail. Results are probabilistic, sometimes ambiguous, and frequently carry emotional weight.

A panel covering several hundred conditions will, for most couples, return at least one carrier finding – which then has to be explained, put in context and, where relevant, matched against a partner’s result before anyone can say what it actually means for that family.

Without expert interpretation, that information can generate more anxiety than insight, which is why credible providers pair the test with genetic counselling rather than returning a bare report.

It is also why integrated models matter: at the London Pregnancy Clinic, screening is built into early pregnancy and fetal-medicine care, so a carrier finding can move straight into a clear next step rather than a referral limbo.

As genomics scales across every life stage, it is this counselling and interpretation capacity – not the sequencing itself – that is fast becoming the real constraint on the system.

The private sector is already running the experiment

For couples who fall outside the NHS’s targeted criteria, comprehensive carrier screening paired with counselling is already available privately – and the infrastructure is more joined-up than the policy debate suggests.

Counsellor-led testing upstream, flowing into specialist prenatal follow-up downstream, is effectively a working prototype of what a preconception-first pathway could look like at scale, operating now while the national system debates whether to widen access.

The window worth widening

None of this argues against sequencing newborns; the early diagnosis of treatable conditions is unequivocally valuable, and the Generation Study will rightly shape policy for years.

But if the national direction of travel is to catch genetic risk as early as possible, the logic points one stage further back than the system currently reaches.

The technology, the panels and the counselling models for preconception screening already exist and are in routine private use. What lags behind is access and routine offer.

As the UK builds out genomics at birth, the most cost-effective expansion of all may prove to be the one that happens before pregnancy even begins – the stage we have, so far, been the quickest to skip.

Disclaimer: This article is intended for general information and industry comment only and does not constitute medical advice, diagnosis or treatment. Population screening policy in the UK is set by the UK National Screening Committee, and individual clinical decisions should be made with a qualified healthcare professional. Information reflects publicly available NHS, Genomics England and UK NSC material as at May 2026. This article was produced in association with Jeen Health. External links are provided for reference only and do not constitute an endorsement of any product, service or organisation.